495 related articles for article (PubMed ID: 29363345)
1. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
2. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
3. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
Kang MJ; Choi JY; Sim WY; Lew BL
J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
[No Abstract] [Full Text] [Related]
4. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
5. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
[TBL] [Abstract][Full Text] [Related]
6. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
7. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
8. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.
Coskuner ER; Ozkan B; Culha MG
Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
Gupta AK; Charrette A
J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair.
Hobo Y; Nishikawa J; Taniguchi Asai N; Yoneyama K; Watanabe Y; Miyashiro Y; Fujikata A
Clin Chim Acta; 2023 Jul; 547():117456. PubMed ID: 37385468
[TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
[TBL] [Abstract][Full Text] [Related]
12. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
[TBL] [Abstract][Full Text] [Related]
14. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
Gupta AK; Talukder M; Williams G
J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
[TBL] [Abstract][Full Text] [Related]
15. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
Lauck KC; Limmer A; Harris P; Kivelevitch D
J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
[No Abstract] [Full Text] [Related]
16. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
17. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
Said MA; Mehta A
Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
[TBL] [Abstract][Full Text] [Related]
19. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
Fertig RM; Gamret AC; Darwin E; Gaudi S
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
Sato A; Takeda A
J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
